English

Eagle Pharmaceuticals, Inc.

EDGAR

EGRX Quarterly report amendment (10-Q/A) · filed 2023-08-09

167 filing records in this dataset, filed from 2013-12-20 to 2023-08-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

64.6 million USD

2023 Q2 · USD

Exact inputs and evidence

Revenue: 64646000 USD Source

Operating margin

15.94%

2023 Q2 · %

Exact inputs and evidence

Operating Income: 10304000 USD Source
Revenue: 64646000 USD Source

Operating cash flow

-126 thousand USD

2023 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -33638000 USD Source
Operating Cash Flow: -33512000 USD Source

Free cash flow

-132 thousand USD

2023 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -33638000 USD Source
Operating Cash Flow: -33512000 USD Source
Capital Expenditure: 64000 USD Source
Capital Expenditure: 58000 USD Source

Cash and cash equivalents: 15.4 million USD 2023-06-30 Source
Exact value

15354000 USD
Long-term debt including current maturities: 71.3 million USD 2023-06-30 Source
Exact value

71250000 USD
Shares outstanding: 15 million shares 2018-06-30 Source
Exact value

15043591 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

258 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Revenue: 65901000 USD · 2022-07-01 – 2022-09-30 Source
Revenue: 316610000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 255911000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 66305000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 64646000 USD · 2023-04-01 – 2023-06-30 Source

Net income

11.9 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Net income: -7131000 USD · 2022-07-01 – 2022-09-30 Source
Net income: 35642000 USD · 2022-01-01 – 2022-12-31 Source
Net income: 27477000 USD · 2022-01-01 – 2022-09-30 Source
Net income: 5750000 USD · 2023-01-01 – 2023-03-31 Source
Net income: 5164000 USD · 2023-04-01 – 2023-06-30 Source

Operating cash flow

-9.32 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: 13144000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: 26381000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: 50701000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: 13144000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -33512000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -33638000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -33512000 USD · 2023-01-01 – 2023-03-31 Source

Capital expenditure

74 thousand USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Capital expenditure: 168000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 168000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 178000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 168000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 58000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 64000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 58000 USD · 2023-01-01 – 2023-03-31 Source

Free cash flow

-9.39 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: 13144000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: 26381000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: 50701000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: 13144000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -33512000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -33638000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -33512000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 168000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 168000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 178000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 168000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 58000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 64000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 58000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-08-09.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2022-12-31
Operating income: 10 of 11 periods available· newest 2022-12-31
Net income: 10 of 11 periods available· newest 2022-12-31
Operating cash flow: 10 of 11 periods available· newest 2022-12-31
Capital expenditure: 10 of 11 periods available· newest 2022-12-31
Total assets: 10 of 11 periods available· newest 2022-12-31
Total liabilities: 5 of 11 periods available· newest 2022-12-31
Current assets: 10 of 11 periods available· newest 2022-12-31
Current liabilities: 10 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2022-12-31
Shares outstanding: 4 of 11 periods available· newest 2017-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+84.6%

Prior period

USD 171.55 million

2021-01-01 – 2021-12-31
Current period

USD 316.61 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

316610000 − 171546000 = 145064000 USD

171546000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
316610000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Year-over-year change in Revenue: 145064000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 316610000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1359651 Filing: 000082787123000009 Input fundies:Revenue: 171546000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1360301 Filing: 000082787123000009
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 44.27 million

Prior period

−USD 8.63 million

2021-01-01 – 2021-12-31
Current period

USD 35.64 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

35642000 − -8627000 = 44269000 USD

-8627000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
35642000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Year-over-year change in Net income: 44269000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 35642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1586079 Filing: 000082787123000009 Input fundies:NetIncome: -8627000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1586915 Filing: 000082787123000009
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+79.7%

Prior period

USD 28.22 million

2021-01-01 – 2021-12-31
Current period

USD 50.7 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

50701000 − 28219000 = 22482000 USD

28219000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
50701000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Year-over-year change in Operating cash flow: 22482000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 50701000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1632813 Filing: 000082787123000009 Input fundies:OperatingCashFlow: 28219000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1633522 Filing: 000082787123000009
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-44.9%

Prior period

USD 323,000

2021-01-01 – 2021-12-31
Current period

USD 178,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

178000 − 323000 = -145000 USD

323000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
178000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Year-over-year change in Capital expenditure: -145000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 178000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1640632 Filing: 000082787123000009 Input fundies:CapitalExpenditure: 323000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1641253 Filing: 000082787123000009
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 316.61 million 100% of revenue
Cost of revenue USD 85.46 million 27% of revenue
Operating expenses USD 140.71 million 44% of revenue
Other operating costs Derived USD 9.48 million 3% of revenue
Operating income USD 80.96 million 26% of revenue
Tax, interest and other Derived USD 45.32 million 14% of revenue
Net income USD 35.64 million 11% of revenue

Cash

Operating cash flow USD 50.7 million 16% of revenue
Capital expenditure USD 178,000 0.1% of revenue
Free cash flow Derived USD 50.52 million 16% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Operating loss: operating costs were 162% of revenue.
2014 Operating loss: operating costs were 198% of revenue.
2015 Net income was higher than operating income, so the split is not drawn.
2016 Net income was higher than operating income, so the split is not drawn.
2017 22%9.3%69%
2018 15%83%
2019 89%
2020 11%82%
2021 Net loss: net income was −5% of revenue.
2022 11%14%74%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2012-10-01 – 2013-09-30	13679000	22134000 Derived	-8455000	-2407000 Derived	-6048000	-5920000 Derived	Source 2012-10-01 – 2013-09-30: 13679000 USD Inspect Revenue Open source 2012-10-01 – 2013-09-30: -8455000 USD Inspect Operating Income Open source 2012-10-01 – 2013-09-30: -6048000 USD Inspect Net Income Open source 2012-10-01 – 2013-09-30: -5879000 USD Inspect Operating Cash Flow Open source 2012-10-01 – 2013-09-30: 41000 USD Inspect Capital Expenditure Open source
2014 2013-10-01 – 2014-09-30	19099000	37856000 Derived	-18757000	-780000 Derived	-17977000	-13889000 Derived	Source 2013-10-01 – 2014-09-30: 19099000 USD Inspect Revenue Open source 2013-10-01 – 2014-09-30: -18757000 USD Inspect Operating Income Open source 2013-10-01 – 2014-09-30: -17977000 USD Inspect Net Income Open source 2013-10-01 – 2014-09-30: -13843000 USD Inspect Operating Cash Flow Open source 2013-10-01 – 2014-09-30: 46000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	66227000	63667000 Derived	2560000	-11000 Derived	2571000	-11599000 Derived	Source 2015-01-01 – 2015-12-31: 66227000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: 2560000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: 2571000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -9718000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 1881000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	189482000	136131000 Derived	53351000	-28102000 Derived	81453000	51617000 Derived	Source 2016-01-01 – 2016-12-31: 189482000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: 53351000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 81453000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 53207000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 1590000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	236707000	162717000 Derived	73990000	22047000 Derived	51943000	54483000 Derived	Source 2017-01-01 – 2017-12-31: 236707000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 73990000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 51943000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 58919000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 4436000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	213312000	176696000 Derived	36616000	4713000 Derived	31903000	52251000 Derived	Source 2018-01-01 – 2018-12-31: 213312000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 36616000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 31903000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 52384000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 133000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	195892000	174077000 Derived	21815000	7502000 Derived	14313000	55209000 Derived	Source 2019-01-01 – 2019-12-31: 195892000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 21815000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 14313000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 55986000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 777000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	187802000	154848000 Derived	32954000	20965000 Derived	11989000	48750000 Derived	Source 2020-01-01 – 2020-12-31: 187802000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 32954000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 11989000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 49497000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 747000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	171546000	168777000 Derived	2769000	11396000 Derived	-8627000	27896000 Derived	Source 2021-01-01 – 2021-12-31: 171546000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 2769000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -8627000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 28219000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 323000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	316610000	235650000 Derived	80960000	45318000 Derived	35642000	50523000 Derived	Source 2022-01-01 – 2022-12-31: 316610000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 80960000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 35642000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 50701000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 178000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 316.6M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-09-30	Revenue	13679000	Revenue: 13679000 Open source
20142014-09-30	Revenue	19099000	Revenue: 19099000 Open source
20152015-12-31	Revenue	66227000	Revenue: 66227000 Open source
20162016-12-31	Revenue	189482000	Revenue: 189482000 Open source
20172017-12-31	Revenue	236707000	Revenue: 236707000 Open source
20182018-12-31	Revenue	213312000	Revenue: 213312000 Open source
20192019-12-31	Revenue	195892000	Revenue: 195892000 Open source
20202020-12-31	Revenue	187802000	Revenue: 187802000 Open source
20212021-12-31	Revenue	171546000	Revenue: 171546000 Open source
20222022-12-31	Revenue	316610000	Revenue: 316610000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

84.6% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-09-30	Year over year	No prior comparable period	Revenue: 13679000 Open source
20142014-09-30	Year over year	39.6%	Revenue: 19099000 Open source Revenue: 13679000 Open source
20152015-12-31	Year over year	No prior comparable period	Revenue: 66227000 Open source
20162016-12-31	Year over year	186.1%	Revenue: 189482000 Open source Revenue: 66227000 Open source
20172017-12-31	Year over year	24.9%	Revenue: 236707000 Open source Revenue: 189482000 Open source
20182018-12-31	Year over year	-9.9%	Revenue: 213312000 Open source Revenue: 236707000 Open source
20192019-12-31	Year over year	-8.2%	Revenue: 195892000 Open source Revenue: 213312000 Open source
20202020-12-31	Year over year	-4.1%	Revenue: 187802000 Open source Revenue: 195892000 Open source
20212021-12-31	Year over year	-8.7%	Revenue: 171546000 Open source Revenue: 187802000 Open source
20222022-12-31	Year over year	84.6%	Revenue: 316610000 Open source Revenue: 171546000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 25.6% 2022

Net margin 11.3% 2022

Free cash flow margin 16% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-09-30	Operating margin	-61.8%	Operating Income: -8455000 Open source Revenue: 13679000 Open source
20142014-09-30	Operating margin	-98.2%	Operating Income: -18757000 Open source Revenue: 19099000 Open source
20152015-12-31	Operating margin	3.9%	Operating Income: 2560000 Open source Revenue: 66227000 Open source
20162016-12-31	Operating margin	28.2%	Operating Income: 53351000 Open source Revenue: 189482000 Open source
20172017-12-31	Operating margin	31.3%	Operating Income: 73990000 Open source Revenue: 236707000 Open source
20182018-12-31	Operating margin	17.2%	Operating Income: 36616000 Open source Revenue: 213312000 Open source
20192019-12-31	Operating margin	11.1%	Operating Income: 21815000 Open source Revenue: 195892000 Open source
20202020-12-31	Operating margin	17.5%	Operating Income: 32954000 Open source Revenue: 187802000 Open source
20212021-12-31	Operating margin	1.6%	Operating Income: 2769000 Open source Revenue: 171546000 Open source
20222022-12-31	Operating margin	25.6%	Operating Income: 80960000 Open source Revenue: 316610000 Open source
20132013-09-30	Net margin	-44.2%	Net Income: -6048000 Open source Revenue: 13679000 Open source
20142014-09-30	Net margin	-94.1%	Net Income: -17977000 Open source Revenue: 19099000 Open source
20152015-12-31	Net margin	3.9%	Net Income: 2571000 Open source Revenue: 66227000 Open source
20162016-12-31	Net margin	43%	Net Income: 81453000 Open source Revenue: 189482000 Open source
20172017-12-31	Net margin	21.9%	Net Income: 51943000 Open source Revenue: 236707000 Open source
20182018-12-31	Net margin	15%	Net Income: 31903000 Open source Revenue: 213312000 Open source
20192019-12-31	Net margin	7.3%	Net Income: 14313000 Open source Revenue: 195892000 Open source
20202020-12-31	Net margin	6.4%	Net Income: 11989000 Open source Revenue: 187802000 Open source
20212021-12-31	Net margin	-5%	Net Income: -8627000 Open source Revenue: 171546000 Open source
20222022-12-31	Net margin	11.3%	Net Income: 35642000 Open source Revenue: 316610000 Open source
20132013-09-30	Free cash flow margin	-43.3%	Revenue: 13679000 Open source Operating Cash Flow: -5879000 Open source Capital Expenditure: 41000 Open source
20142014-09-30	Free cash flow margin	-72.7%	Revenue: 19099000 Open source Operating Cash Flow: -13843000 Open source Capital Expenditure: 46000 Open source
20152015-12-31	Free cash flow margin	-17.5%	Revenue: 66227000 Open source Operating Cash Flow: -9718000 Open source Capital Expenditure: 1881000 Open source
20162016-12-31	Free cash flow margin	27.2%	Revenue: 189482000 Open source Operating Cash Flow: 53207000 Open source Capital Expenditure: 1590000 Open source
20172017-12-31	Free cash flow margin	23%	Revenue: 236707000 Open source Operating Cash Flow: 58919000 Open source Capital Expenditure: 4436000 Open source
20182018-12-31	Free cash flow margin	24.5%	Revenue: 213312000 Open source Operating Cash Flow: 52384000 Open source Capital Expenditure: 133000 Open source
20192019-12-31	Free cash flow margin	28.2%	Revenue: 195892000 Open source Operating Cash Flow: 55986000 Open source Capital Expenditure: 777000 Open source
20202020-12-31	Free cash flow margin	26%	Revenue: 187802000 Open source Operating Cash Flow: 49497000 Open source Capital Expenditure: 747000 Open source
20212021-12-31	Free cash flow margin	16.3%	Revenue: 171546000 Open source Operating Cash Flow: 28219000 Open source Capital Expenditure: 323000 Open source
20222022-12-31	Free cash flow margin	16%	Revenue: 316610000 Open source Operating Cash Flow: 50701000 Open source Capital Expenditure: 178000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 50.7M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-09-30	Operating cash flow	-5879000	Operating Cash Flow: -5879000 Open source
20142014-09-30	Operating cash flow	-13843000	Operating Cash Flow: -13843000 Open source
20152015-12-31	Operating cash flow	-9718000	Operating Cash Flow: -9718000 Open source
20162016-12-31	Operating cash flow	53207000	Operating Cash Flow: 53207000 Open source
20172017-12-31	Operating cash flow	58919000	Operating Cash Flow: 58919000 Open source
20182018-12-31	Operating cash flow	52384000	Operating Cash Flow: 52384000 Open source
20192019-12-31	Operating cash flow	55986000	Operating Cash Flow: 55986000 Open source
20202020-12-31	Operating cash flow	49497000	Operating Cash Flow: 49497000 Open source
20212021-12-31	Operating cash flow	28219000	Operating Cash Flow: 28219000 Open source
20222022-12-31	Operating cash flow	50701000	Operating Cash Flow: 50701000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 50.5M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-09-30	Free cash flow	-5920000	Operating Cash Flow: -5879000 Open source Capital Expenditure: 41000 Open source
20142014-09-30	Free cash flow	-13889000	Operating Cash Flow: -13843000 Open source Capital Expenditure: 46000 Open source
20152015-12-31	Free cash flow	-11599000	Operating Cash Flow: -9718000 Open source Capital Expenditure: 1881000 Open source
20162016-12-31	Free cash flow	51617000	Operating Cash Flow: 53207000 Open source Capital Expenditure: 1590000 Open source
20172017-12-31	Free cash flow	54483000	Operating Cash Flow: 58919000 Open source Capital Expenditure: 4436000 Open source
20182018-12-31	Free cash flow	52251000	Operating Cash Flow: 52384000 Open source Capital Expenditure: 133000 Open source
20192019-12-31	Free cash flow	55209000	Operating Cash Flow: 55986000 Open source Capital Expenditure: 777000 Open source
20202020-12-31	Free cash flow	48750000	Operating Cash Flow: 49497000 Open source Capital Expenditure: 747000 Open source
20212021-12-31	Free cash flow	27896000	Operating Cash Flow: 28219000 Open source Capital Expenditure: 323000 Open source
20222022-12-31	Free cash flow	50523000	Operating Cash Flow: 50701000 Open source Capital Expenditure: 178000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

42.5% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-09-30	Liabilities / assets	Not reported	Total Assets: 18103000 Open source
2014-09-30	Liabilities / assets	Not reported	Total Assets: 53411000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 124605000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 214320000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 270060000 Open source
20182018-12-31	Liabilities / assets	32.6%	Total Liabilities: 77841000 Open source Total Assets: 238603000 Open source
20192019-12-31	Liabilities / assets	29.6%	Total Liabilities: 75380000 Open source Total Assets: 254554000 Open source
20202020-12-31	Liabilities / assets	26.5%	Total Liabilities: 67179000 Open source Total Assets: 253190000 Open source
20212021-12-31	Liabilities / assets	30.5%	Total Liabilities: 77279000 Open source Total Assets: 253732000 Open source
20222022-12-31	Liabilities / assets	42.5%	Total Liabilities: 172600000 Open source Total Assets: 406160000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.7× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-09-30	Current assets / current liabilities	1.22×	Current Assets: 17483000 Open source Current Liabilities: 14342000 Open source
20142014-09-30	Current assets / current liabilities	2.61×	Current Assets: 53022000 Open source Current Liabilities: 20315000 Open source
20152015-12-31	Current assets / current liabilities	3.57×	Current Assets: 122257000 Open source Current Liabilities: 34262000 Open source
20162016-12-31	Current assets / current liabilities	2.66×	Current Assets: 109110000 Open source Current Liabilities: 40965000 Open source
20172017-12-31	Current assets / current liabilities	3.99×	Current Assets: 188697000 Open source Current Liabilities: 47302000 Open source
20182018-12-31	Current assets / current liabilities	4.13×	Current Assets: 163844000 Open source Current Liabilities: 39686000 Open source
20192019-12-31	Current assets / current liabilities	4.62×	Current Assets: 179449000 Open source Current Liabilities: 38823000 Open source
20202020-12-31	Current assets / current liabilities	4.36×	Current Assets: 166065000 Open source Current Liabilities: 38085000 Open source
20212021-12-31	Current assets / current liabilities	2.32×	Current Assets: 172606000 Open source Current Liabilities: 74376000 Open source
20222022-12-31	Current assets / current liabilities	1.7×	Current Assets: 188754000 Open source Current Liabilities: 111087000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2012-10-01 – 2013-09-30	−USD 6.05 million Exact value Exact value: -6048000 USD 2012-10-01 – 2013-09-30: -6048000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2013-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: -6048000 USD Concept: fundies:NetIncome Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2013-09-30&surface=latest&period_type=duration&start=2012-10-01&unit=USD&dimensions= Input fundies:NetIncome: -6048000 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787116000049/egrx-20151231.xml#337570 Filing: 000082787116000049 The citation records this snapshot. The page link may show a newer release later.	−USD 5.88 million Exact value Exact value: -5879000 USD 2012-10-01 – 2013-09-30: -5879000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2013-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: -5879000 USD Concept: fundies:OperatingCashFlow Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2013-09-30&surface=latest&period_type=duration&start=2012-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5879000 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787116000049/egrx-20151231.xml#336722 Filing: 000082787116000049 The citation records this snapshot. The page link may show a newer release later.	USD 41,000 Exact value Exact value: 41000 USD 2012-10-01 – 2013-09-30: 41000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2013-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 41000 USD Concept: fundies:CapitalExpenditure Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2013-09-30&surface=latest&period_type=duration&start=2012-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 41000 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787116000049/egrx-20151231.xml#353179 Filing: 000082787116000049 The citation records this snapshot. The page link may show a newer release later.	−USD 5.92 million Calculation and evidence -5879000 − 41000 USD Exact free cash flow: -5920000 USD 2012-10-01 – 2013-09-30: -5879000 USD · Inspect Operating Cash Flow · Source 2012-10-01 – 2013-09-30: 41000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2013-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: -5920000 USD Concept: free-cash-flow Period: 2012-10-01 to 2013-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5879000 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787116000049/egrx-20151231.xml#336722 Filing: 000082787116000049 Input fundies:CapitalExpenditure: 41000 USD (2012-10-01 to 2013-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787116000049/egrx-20151231.xml#353179 Filing: 000082787116000049 The citation records this snapshot. The page link may show a newer release later.
2014 2013-10-01 – 2014-09-30	−USD 17.98 million Exact value Exact value: -17977000 USD 2013-10-01 – 2014-09-30: -17977000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2014-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: -17977000 USD Concept: fundies:NetIncome Period: 2013-10-01 to 2014-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2014-09-30&surface=latest&period_type=duration&start=2013-10-01&unit=USD&dimensions= Input fundies:NetIncome: -17977000 USD (2013-10-01 to 2014-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787117000002/egrx-20161231.xml#353919 Filing: 000082787117000002 The citation records this snapshot. The page link may show a newer release later.	−USD 13.84 million Exact value Exact value: -13843000 USD 2013-10-01 – 2014-09-30: -13843000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2014-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: -13843000 USD Concept: fundies:OperatingCashFlow Period: 2013-10-01 to 2014-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2014-09-30&surface=latest&period_type=duration&start=2013-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13843000 USD (2013-10-01 to 2014-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787117000002/egrx-20161231.xml#353072 Filing: 000082787117000002 The citation records this snapshot. The page link may show a newer release later.	USD 46,000 Exact value Exact value: 46000 USD 2013-10-01 – 2014-09-30: 46000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2014-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 46000 USD Concept: fundies:CapitalExpenditure Period: 2013-10-01 to 2014-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2014-09-30&surface=latest&period_type=duration&start=2013-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 46000 USD (2013-10-01 to 2014-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787117000002/egrx-20161231.xml#375056 Filing: 000082787117000002 The citation records this snapshot. The page link may show a newer release later.	−USD 13.89 million Calculation and evidence -13843000 − 46000 USD Exact free cash flow: -13889000 USD 2013-10-01 – 2014-09-30: -13843000 USD · Inspect Operating Cash Flow · Source 2013-10-01 – 2014-09-30: 46000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2014-09-30 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: -13889000 USD Concept: free-cash-flow Period: 2013-10-01 to 2014-09-30 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13843000 USD (2013-10-01 to 2014-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787117000002/egrx-20161231.xml#353072 Filing: 000082787117000002 Input fundies:CapitalExpenditure: 46000 USD (2013-10-01 to 2014-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787117000002/egrx-20161231.xml#375056 Filing: 000082787117000002 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	USD 2.57 million Exact value Exact value: 2571000 USD 2015-01-01 – 2015-12-31: 2571000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2015-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: 2571000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: 2571000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787118000003/egrx-20171231.xml#213826 Filing: 000082787118000003 The citation records this snapshot. The page link may show a newer release later.	−USD 9.72 million Exact value Exact value: -9718000 USD 2015-01-01 – 2015-12-31: -9718000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2015-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: -9718000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9718000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787118000003/egrx-20171231.xml#213193 Filing: 000082787118000003 The citation records this snapshot. The page link may show a newer release later.	USD 1.88 million Exact value Exact value: 1881000 USD 2015-01-01 – 2015-12-31: 1881000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2015-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 1881000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1881000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787118000003/egrx-20171231.xml#228454 Filing: 000082787118000003 The citation records this snapshot. The page link may show a newer release later.	−USD 11.6 million Calculation and evidence -9718000 − 1881000 USD Exact free cash flow: -11599000 USD 2015-01-01 – 2015-12-31: -9718000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1881000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2015-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: -11599000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9718000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787118000003/egrx-20171231.xml#213193 Filing: 000082787118000003 Input fundies:CapitalExpenditure: 1881000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787118000003/egrx-20171231.xml#228454 Filing: 000082787118000003 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	USD 81.45 million Exact value Exact value: 81453000 USD 2016-01-01 – 2016-12-31: 81453000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2016-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: 81453000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: 81453000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787119000008/egrx-20181231.xml#229818 Filing: 000082787119000008 The citation records this snapshot. The page link may show a newer release later.	USD 53.21 million Exact value Exact value: 53207000 USD 2016-01-01 – 2016-12-31: 53207000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2016-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: 53207000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 53207000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787119000008/egrx-20181231.xml#229185 Filing: 000082787119000008 The citation records this snapshot. The page link may show a newer release later.	USD 1.59 million Exact value Exact value: 1590000 USD 2016-01-01 – 2016-12-31: 1590000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2016-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 1590000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1590000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787119000008/egrx-20181231.xml#245603 Filing: 000082787119000008 The citation records this snapshot. The page link may show a newer release later.	USD 51.62 million Calculation and evidence 53207000 − 1590000 USD Exact free cash flow: 51617000 USD 2016-01-01 – 2016-12-31: 53207000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 1590000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2016-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: 51617000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 53207000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787119000008/egrx-20181231.xml#229185 Filing: 000082787119000008 Input fundies:CapitalExpenditure: 1590000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787119000008/egrx-20181231.xml#245603 Filing: 000082787119000008 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 51.94 million Exact value Exact value: 51943000 USD 2017-01-01 – 2017-12-31: 51943000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2017-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: 51943000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 51943000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787120000007/egrx10k2019.htm#1836295 Filing: 000082787120000007 The citation records this snapshot. The page link may show a newer release later.	USD 58.92 million Exact value Exact value: 58919000 USD 2017-01-01 – 2017-12-31: 58919000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2017-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: 58919000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 58919000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787120000007/egrx10k2019.htm#1599232 Filing: 000082787120000007 The citation records this snapshot. The page link may show a newer release later.	USD 4.44 million Exact value Exact value: 4436000 USD 2017-01-01 – 2017-12-31: 4436000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2017-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 4436000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4436000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787120000007/egrx10k2019.htm#1604010 Filing: 000082787120000007 The citation records this snapshot. The page link may show a newer release later.	USD 54.48 million Calculation and evidence 58919000 − 4436000 USD Exact free cash flow: 54483000 USD 2017-01-01 – 2017-12-31: 58919000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4436000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2017-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: 54483000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 58919000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787120000007/egrx10k2019.htm#1599232 Filing: 000082787120000007 Input fundies:CapitalExpenditure: 4436000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787120000007/egrx10k2019.htm#1604010 Filing: 000082787120000007 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 31.9 million Exact value Exact value: 31903000 USD 2018-01-01 – 2018-12-31: 31903000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2018-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: 31903000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 31903000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787121000011/egrx-20201231.htm#1876421 Filing: 000082787121000011 The citation records this snapshot. The page link may show a newer release later.	USD 52.38 million Exact value Exact value: 52384000 USD 2018-01-01 – 2018-12-31: 52384000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2018-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: 52384000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 52384000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787121000011/egrx-20201231.htm#1558169 Filing: 000082787121000011 The citation records this snapshot. The page link may show a newer release later.	USD 133,000 Exact value Exact value: 133000 USD 2018-01-01 – 2018-12-31: 133000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2018-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 133000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 133000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787121000011/egrx-20201231.htm#1562321 Filing: 000082787121000011 The citation records this snapshot. The page link may show a newer release later.	USD 52.25 million Calculation and evidence 52384000 − 133000 USD Exact free cash flow: 52251000 USD 2018-01-01 – 2018-12-31: 52384000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 133000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2018-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: 52251000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 52384000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787121000011/egrx-20201231.htm#1558169 Filing: 000082787121000011 Input fundies:CapitalExpenditure: 133000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787121000011/egrx-20201231.htm#1562321 Filing: 000082787121000011 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 14.31 million Exact value Exact value: 14313000 USD 2019-01-01 – 2019-12-31: 14313000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2019-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: 14313000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 14313000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787122000008/egrx-20211231.htm#1486540 Filing: 000082787122000008 The citation records this snapshot. The page link may show a newer release later.	USD 55.99 million Exact value Exact value: 55986000 USD 2019-01-01 – 2019-12-31: 55986000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2019-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: 55986000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 55986000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787122000008/egrx-20211231.htm#1546379 Filing: 000082787122000008 The citation records this snapshot. The page link may show a newer release later.	USD 777,000 Exact value Exact value: 777000 USD 2019-01-01 – 2019-12-31: 777000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2019-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 777000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 777000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787122000008/egrx-20211231.htm#1553787 Filing: 000082787122000008 The citation records this snapshot. The page link may show a newer release later.	USD 55.21 million Calculation and evidence 55986000 − 777000 USD Exact free cash flow: 55209000 USD 2019-01-01 – 2019-12-31: 55986000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 777000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2019-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: 55209000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 55986000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787122000008/egrx-20211231.htm#1546379 Filing: 000082787122000008 Input fundies:CapitalExpenditure: 777000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787122000008/egrx-20211231.htm#1553787 Filing: 000082787122000008 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 11.99 million Exact value Exact value: 11989000 USD 2020-01-01 – 2020-12-31: 11989000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2020-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: 11989000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 11989000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1913247 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 49.5 million Exact value Exact value: 49497000 USD 2020-01-01 – 2020-12-31: 49497000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2020-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: 49497000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 49497000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1634231 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 747,000 Exact value Exact value: 747000 USD 2020-01-01 – 2020-12-31: 747000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2020-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 747000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 747000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1641874 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 48.75 million Calculation and evidence 49497000 − 747000 USD Exact free cash flow: 48750000 USD 2020-01-01 – 2020-12-31: 49497000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 747000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2020-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: 48750000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 49497000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1634231 Filing: 000082787123000009 Input fundies:CapitalExpenditure: 747000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1641874 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 8.63 million Exact value Exact value: -8627000 USD 2021-01-01 – 2021-12-31: -8627000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2021-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: -8627000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8627000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1586915 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 28.22 million Exact value Exact value: 28219000 USD 2021-01-01 – 2021-12-31: 28219000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2021-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: 28219000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 28219000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1633522 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 323,000 Exact value Exact value: 323000 USD 2021-01-01 – 2021-12-31: 323000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2021-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 323000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 323000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1641253 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 27.9 million Calculation and evidence 28219000 − 323000 USD Exact free cash flow: 27896000 USD 2021-01-01 – 2021-12-31: 28219000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 323000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2021-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: 27896000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 28219000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1633522 Filing: 000082787123000009 Input fundies:CapitalExpenditure: 323000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1641253 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 35.64 million Exact value Exact value: 35642000 USD 2022-01-01 – 2022-12-31: 35642000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Net Income: 35642000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 35642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1586079 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 50.7 million Exact value Exact value: 50701000 USD 2022-01-01 – 2022-12-31: 50701000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Operating Cash Flow: 50701000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 50701000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1632813 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 178,000 Exact value Exact value: 178000 USD 2022-01-01 – 2022-12-31: 178000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Capital Expenditure: 178000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 178000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1640632 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.	USD 50.52 million Calculation and evidence 50701000 − 178000 USD Exact free cash flow: 50523000 USD 2022-01-01 – 2022-12-31: 50701000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 178000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Eagle Pharmaceuticals, Inc. · 2022-12-31 Eagle Pharmaceuticals, Inc. (edgar:827871) Free cash flow: 50523000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:41:39Z Snapshot: 4555699870c8237886fa2175ba77244c0f41b423c4bc0434b30913136b78f598 Dimensions: Consolidated View: https://fundies.io/companies/edgar/827871?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 50701000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1632813 Filing: 000082787123000009 Input fundies:CapitalExpenditure: 178000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/827871/000082787123000009/egrx-20221231.htm#1640632 Filing: 000082787123000009 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

167 filings · 3,552 latest values · 3,552 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000827871, 827871, EGRX, edgar:827871

Also known as EAGLE PHARMACEUTICALS INC, EAGLE PHARMACEUTICALS, INC., Eagle Pharmaceuticals, Inc., Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation